Clinical trials: Alzheimer's Disease - MCI
Alzheimer Disease
Study With Lu AF20513 in Patients With Mild Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI) Due to AD
The purpose of this study is to study the effect of monthly dosing with a single dose of Lu AF20513, with and without booster vaccine, on antibody response.
- Trial name
- NCT03819699
- Testing
- Lu AF20513, booster vaccine
- Where
- 3 sites in Finland, Sweden
- Volunteers
- 3 people
- Sponsor
- H. Lundbeck A/S
Alzheimer Disease, Dementia
Reducing Dementia Risk With Digital Health Coaching
The Digital Cognitive Multi-domain Alzheimer's Risk Velocity (DC MARVEL) study is a 2-year randomized controlled trial on dementia prevention.
- Conditions
- Alzheimer Disease, Dementia, Mild Cognitive Impairment, Cognitive Decline
- Trial name
- DC-MARVEL (NCT04559789)
- Testing
- MindMate + Health Coaching, Health Education
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Neurotrack Technologies, Inc.
Mild Cognitive Impairment
Beta-Amyloid Imaging With [18F]NAV4694 PET in Predicting Progression to AD in Subjects MCI
To investigate whether [18F]NAV4694 positron emission tomography (PET) scan findings have the ability to distinguish subjects with mild cognitive impairment (MCI) who progress to Alzheimer's disease (AD) from those who do not.
- Trial name
- NAV4-04 (NCT01812213)
- Testing
- [18F]NAV4694
- Where
- 11 sites in United States
- Volunteers
- 76 people
- Sponsor
- Navidea Biopharmaceuticals
Alzheimer Disease
A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease
The study involves repeated doses of LY3303560 given by infusion for 49 weeks. The study will examine how safe repeated doses of LY3303560 are, whether they cause side effects in participants with mild cognitive impairment or…
- Trial name
- NCT03019536
- Testing
- LY3303560 - IV, Florbetapir F 18, Flortaucipir F18
- Where
- 11 sites in United States, Japan and 1 more
- Volunteers
- 22 people
- Sponsor
- Eli Lilly and Company
Mild Cognitive Impairment, Alzheimer's Disease
Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease
This study will investigate the efficacy of the Flutemetamol (18F) Injection PET tracer in identifying abnormal (18F) flutemetamol uptake patterns which predict the conversion from aMCI to a b-amyloid associated clinically…
- Trial name
- NCT01028053
- Testing
- Flutemetamol (18F) Injection
- Where
- United States
- Volunteers
- 365 people
- Sponsor
- GE Healthcare
Alzheimer's Disease, Mild Cognitive Impairment
Trial of Novel Oral Zinc Cysteine Preparation in Alzheimer's Disease
This trial aims to test the hypothesis that 1) a single dose of zinc cysteine in a proprietary gastro-retentive form will produce sustained blood levels of zinc giving a larger bioavailable amount of zinc than an FDA approved…
- Trial name
- NCT01099332
- Testing
- Gastro-retentive zinc cysteine tablet, Tablet identical physically to active comparator containing some lactose
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Adeona Pharmaceuticals
Alzheimer s Disease, Mild Cognitive Impairment (MCI)
Crownlands Observing Progression With Neurons Study
The CROWN-I Study is an observational study to learn about molecular features of Alzheimer's disease (AD) and mild cognitive impairment (MCI).
- Trial name
- CROWN-I (NCT07611396)
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Crownlands
Mild Cognitive Impairment, Mild Dementia
A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Alzheimer's Disease.
- Conditions
- Mild Cognitive Impairment, Mild Dementia, Alzheimer's Disease
- Trial name
- NCT05619692
- Testing
- SAGE-718
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 174 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Cognitive Impairment, Alzheimer Disease
Validation of a Smartphone Application for the Assessment of Patients With Mild Cognitive Impairment: MemScreen
The clinical evaluation of a patient with a cognitive complaint requires neuropsychological tests, evaluating the integrity of memory and other cognitive functions.
- Trial name
- MemScreen (NCT03811184)
- Testing
- MemScreen
- Where
- France
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- MemScreen
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease, Early Onset
Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)
Alzheimer's disease (AD) is the most common form of dementia. In the brains of people with AD, certain small substances stick together. This leads to changes in thinking and behaviour.
- Trial name
- PRImus-AD (NCT06182085)
- Testing
- PRI-002
- Where
- 38 sites in Czechia, Germany and 4 more
- Volunteers
- 304 people
- Sponsor
- PRInnovation GmbH
Alzheimer Disease
A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD
This is a Phase 2A multi-center, randomized, double blind, placebo-controlled, parallel group study of varoglutamstat, with a stage gate to Phase 2B.
- Trial name
- VIVA-MIND (NCT03919162)
- Testing
- PQ912
- Where
- 22 sites in United States
- Volunteers
- 112 people
- Sponsor
- Vivoryon Therapeutics N.V.
Alzheimer Disease, Chronic Traumatic Encephalopathy
Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease
CMK-0301 is a multi-site, randomized clinical trial to evaluate the safety and efficacy of [F-18]Flornaptitril-PET (F-18 FNT-PET) for the prediction of clinical progression of Mild Cognitive Impairment (MCI) with either Suspected…
- Trial name
- NCT06254469
- Testing
- [F-18]Flornaptitril
- Where
- United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- CereMark Pharma, LLC
Alzheimer Disease, MCI
Detecting an MCI and Amyloid Digital Neuro Signature(DNS) Using Altoida's Multimodal Digital Biomarkers.
The purpose of this study is to establish multiple points of clinical validity for the Altoida digital biomarker assessment in individuals with a clinical diagnosis of cognitively normal (CN) and Mild Cognitive Impairment (MCI).
- Trial name
- NCT06223438
- Where
- United States
- Volunteers
- 614 people, healthy volunteers welcome
- Sponsor
- Altoida
Mild Cognitive Impairment, Alzheimer's Disease
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective.
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss
- Trial name
- Bio-Hermes-002 (NCT06584357)
- Testing
- Biomarker Data Collection, MK6240
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- GAP Innovations, PBC
Alzheimer's Disease (AD)
A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR-1707 in patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD for 26 weeks.
- Trial name
- NCT06114745
- Testing
- SHR-1707 injection
- Where
- 3 sites in Australia
- Volunteers
- 2 people
- Sponsor
- Atridia Pty Ltd.
Mild Cognitive Impairment
Efficacy and Safety of T-817MA in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD
Primary objective is to evaluate the neuroprotective effect of T-817MA on Tau protein phosphorylated at threonine 181 (p-tau 181) in cerebrospinal fluid (CSF) compared with placebo in patients with a diagnosis of MCI due to AD or…
- Trial name
- NCT04191486
- Testing
- T-817MA
- Where
- 37 sites in Czechia, Germany and 5 more
- Volunteers
- 221 people
- Sponsor
- FUJIFILM Toyama Chemical Co., Ltd.
Alzheimer's Disease, Mild Cognitive Impairment
Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center
The purpose of this study is to assess the performance of AclarusDx™, an investigational blood test detecting gene expression information, and intended to help physicians in making an Alzheimer's Disease diagnosis in patients…
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, Vascular Dementia, Fronto-temporal Dementia
- Trial name
- NCT01465360
- Where
- 3 sites in United States
- Volunteers
- 160 people
- Sponsor
- Exonhit
Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia
Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function
This study is to evaluate the efficacy and safety of [18F]-APN-1607 Injection in PET imaging for detecting AD-related cognitive impairment.
- Trial name
- NCT07422857
- Testing
- [18F]-APN-1607
- Where
- 2 sites in China
- Volunteers
- 316 people, healthy volunteers welcome
- Sponsor
- JYAMS PET Research & Development Limited
Alzheimer's Disease, Mild Cognitive Impairment
A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)
Evaluate florbetapir (18F) positron emission tomography (PET) imaging for distinguishing Japanese healthy control subjects, from Japanese subjects with Alzheimer's disease (AD) or Mild cognitive impairment (MCI).
- Trial name
- NCT01662882
- Testing
- florbetapir (18F)
- Where
- 2 sites in Japan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer's Disease
A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)
The purpose of this study is to evaluate the safety and tolerability of the study drug, LY3303560. Side effects and laboratory results will be monitored.
- Trial name
- NCT02754830
- Testing
- LY3303560 - IV, Saline Solution - IV, LY3303560 - SC
- Where
- 2 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company